Meduloc has raised $4 million in Series B funding to support the controlled commercialization of its FDA-cleared fracture fixation platform. GenHenn Capital led the financing, with participation from Life Sciences Greenhouse Investments, Ben Franklin Technology Partners of Southeastern Pennsylvania, Broad Street Angels, former Major League Baseball All-Star Andre Ethier, and additional existing and new investors.
The funding will support Meduloc’s controlled alpha launch, continued collection of clinical evidence, and development of the commercial infrastructure needed to expand availability of its technology to more surgeons and patients.
Meduloc’s sterile, single-use system uses a flexible nitinol intramedullary implant designed to stabilize fractures while preserving anatomy and avoiding joint violation in certain procedures.
The FDA-cleared platform can be used across multiple upper- and lower-extremity long-bone fracture applications in both adult and pediatric patients.
Meduloc plans to work with a select group of orthopedic surgeons and institutions during its controlled launch to develop additional clinical experience, gather surgeon feedback, and prepare for broader commercial expansion.
KEY QUOTES:
“Closing this financing is a significant milestone for Meduloc as we move from product development and regulatory clearance into controlled commercialization. We are extremely grateful for the confidence and support of our investors, and particularly proud of the strong backing we have received from the Greater Philadelphia and Pennsylvania life sciences and investment communities.”
Sarah Sachinis, President and CEO of Meduloc
“Meduloc has developed a differentiated technology with the potential to address important needs in fracture fixation. With FDA clearance, encouraging early clinical experience and an experienced team, the company has reached an exciting inflection point. We are pleased to lead this financing and support Meduloc as it enters its next phase of growth.”
Bill Hagaman, GenHenn Capital
“As a former professional athlete, I have seen how injuries and recovery can affect both performance and quality of life. Meduloc’s approach stood out to me because of its potential to provide surgeons with an innovative treatment option and help patients return to the activities that matter to them. I’m excited to support the team as it brings this technology into broader clinical use.”
Andre Ethier, Investor and Former Major League Baseball All-Star
